VANCOUVER, British Columbia, Jan. 23, 2018 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE:BLO) (OTC:BLOZF) (the “Company or Cannabix”) developer of the Cannabix Marijuana Breathalyzer for law enforcement and the workplace, is pleased to report development of its “Beta 3.0” (Cannabix Marijuana Breathalyzer) prototype device based on its FAIMS- (field asymmetric waveform ion mobility spectrometry) has been proceeding at a robust pace and is now complete. This device is designed to operate both independently or coupled in tandem directly to a conventional Quadrupole Mass Spectrometer (MS) device used in forensic labs.
The Beta 3.0 prototype incorporates several key technological improvements which include enhancements to the ion source which, for portability, has been reduced in size with sustained stability, providing improvements to transmission and overall device sensitivity. The Beta 3.0 prototype also incorporates its own tunable self-contained detector which can be used in both independent FAIMS operation or in “pass-through” mode for tandem coupling directly with a MS device.
Chief Scientific Officer, Dr. Raj Attariwala, states, “With completion of the modular Beta 3.0 prototype, Cannabix has achieved several key developmental milestones allowing this technology to be directly tested against the accepted laboratory standard of mass spectrometry”.
The Company has performed preliminary bench testing with the Beta 3.0 prototype and has successfully detected THC using the device in stand-alone mode with tandem MS analysis demonstrating direct correlation. This is a significant developmental milestone which the Company will use to optimize and characterize the device’s performance measures both independently and coupled to MS.
Cannabix has been on the leading edge in innovation with FAIMS technology built upon the current technique of MS for measuring THC. MS is considered the gold standard in toxicology in the analysis of drugs, poisons, and metabolites, due to its superior specificity and sensitivity. It is anticipated that any marijuana breathalyzer product will need to have its results be secondarily confirmed by independent MS. Recent work by Company scientists and engineers to allow the Cannabix Marijuana breathalyzer to easily couple to conventional MS equipment used in toxicology labs everywhere is a significant achievement.
About Cannabix Technologies Inc.
Cannabix Technologies Inc. is a leader in marijuana breathalyzer development for law enforcement and the workplace. Cannabix has established breath testing technologies in the pursuit of bringing durable, portable hand-held tools to market to enhance detection of marijuana impaired driving offences on roads at a time when marijuana is becoming legal in many global jurisdictions. Cannabix is working to develop drug-testing devices that will detect THC- the psychoactive component of marijuana that causes intoxication- using breath samples. In particular, Cannabix is focused on developing breath testing devices for detection of recent use of THC, in contrast to urine testing for THC metabolite that requires an invasive collection and reflects use days or even weeks earlier. The devices will also be useful for other practical applications such as testing employees in the workplace where intoxication by THC can be hazardous.
We seek Safe Harbor.
On behalf of the Board of Directors
Cannabix Technologies Inc.
For further information, contact the Company at email@example.com
The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking information that involves various risks and uncertainties regarding future events. Such forward-looking information can include without limitation statements based on current expectations involving a number of risks and uncertainties and are not guarantees of future performance of the Company, such as final development of a commercial or prototype product(s), successful trial or pilot of company technologies, no assurance that commercial sales of any kind actually materialize; no assurance the Company will have sufficient funds to complete product development. There are numerous risks and uncertainties that could cause actual results and the Company’s plans and objectives to differ materially from those expressed in the forward-looking information, including: (i) adverse market conditions; (ii) risks regarding protection of proprietary technology; (iii) the ability of the Company to complete financings; (iv) the ability of the Company to develop and market its future product; and (v) risks regarding government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition and other factors which may be identified from time to time in the Company's public announcements and filings. There is no assurance that the marijuana breathalyzer business will provide any benefit to the Company, and no assurance that any proposed new products will be built or proceed. There is no assurance that existing “patent pending” technologies licensed by the Company will receive patent status by regulatory authorities. The Company is not currently selling commercial breathalyzers. Actual results and future events could differ materially from those anticipated in such information. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, the Company does not intend to update these forward-looking statements.